
For patients previously on phosphate binders (sevelamer hydrochloride or calcium based), Sevelamer Carbonate (Corvelam) should be given on a gram for gram basis with monitoring of serum phosphorus levels to ensure optimal daily doses.
Titration and Maintenance: Serum phosphorus levels must be monitored and the dose of sevelamer carbonate titrated by 0.8 g three times per day (2.4 g/day) increments every 2-4 weeks until an acceptable serum phosphorus level is reached, with regular monitoring thereafter.
Patients taking Sevelamer Carbonate (Corvelam) should adhere to their prescribed diets.
In clinical practice, treatment will be continuous based on the need to control serum phosphorus levels and the daily dose is expected to be an average of approximately 6 g per day.
Pediatric population: The safety and efficacy of Sevelamer Carbonate (Corvelam) have not been established in children below the age of 18 years.
Sevelamer Carbonate (Corvelam) is not recommended in children below the age of 18 years.
Method of administration: For oral use.
Tablets should be swallowed intact and should not be crushed, chewed, or broken into pieces prior to administration.